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BACKGROUND In Multicenter Automatic Defibrillator Implantation
Trial – Reduce Inappropriate Therapy (MADIT-RIT), high-rate cutoff
(arm B) and delayed therapy (arm C) reduced the risk of inappro-
priate implantable cardioverter-defibrillator (ICD) interventions
when compared with conventional programming (arm A); however,
appropriate but unnecessary therapies were not evaluated.
OBJECTIVE The purpose of this study was to assess the value of
antitachycardia pacing (ATP) for fast ventricular arrhythmias
(VAs)  200 beats/min in patients with primary prevention ICD.
METHODS We compared ATP only, ATP and shock, and shock only
rates in patients in MADIT-RIT treated for VAs  200 beats/min.
The only difference between these randomized groups was the
time delay between ventricular tachycardia detection and therapy
(3.4 seconds vs 4.9 seconds vs 14.4 seconds).
RESULTS In arm A, 11.5% patients had events, the initial therapy
was ATP in 10.5% and shock in 1%, and the final therapy was ATP in
8% and shock in 3.5%. In arm B, 6.6% had events, 4.2% were
initially treated with ATP and 2.4% with shock, and the final therapy
was ATP in 2.8% and shock in 3.8%. In arm C, 4.7% had events,
2.5% were initially treated with ATP and 2.3% with shock, and
the final therapy was ATP in 1.4% and shock in 3.3%. The final shock
rate was similar in arm A vs arm B (3.5% vs 3.8%; P5 .800) and in
arm A vs arm C (3.5% vs 3.3%; P 5 .855) despite the marked
discrepancy in initial ATP therapy utilization.
CONCLUSION In MADIT-RIT, there was a significant reduction in
ATP interventions with therapy delays due to spontaneous termina-
tion, with no difference in shock therapies, suggesting that earlier
interventions for VAs 200 beats/min are likely unnecessary, lead-
ing to an overestimation of the value of ATP in primary prevention
ICD recipients.
KEYWORDS Antitachycardia pacing therapy; ICD; Ventricular
arrhythmia; Ventricular fibrillation; Ventricular tachycardia
(Heart Rhythm 2021;18:399–403) © 2020 Heart Rhythm Society.
This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Introduction
Data from multiple randomized controlled clinical trials, reg-
istries, and observational studies indicate that patients at risk
for sudden cardiac death with reduced left ventricular ejec-
tion fraction and heart failure derive a survival benefit from
implantable cardioverter-defibrillators (ICDs), either alone
or in conjunction with cardiac resynchronization therapy
(CRT). However, the occurrence of supraventricular arrhyth-
mias such as atrial fibrillation or flutter or non–life-threat-
ening, nonsustained ventricular tachycardias (VTs) may
result in either inappropriate therapy or prematurely applied,
unnecessary therapy and is a direct consequence of specific
device parameter programming.1,2 Inappropriate or prema-
ture ICD interventions have previously been shown to be
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associated with an impaired quality of life3,4 and potentially
an increased risk of all-cause mortality.1,5
The Multicenter Automatic Defibrillator Implantation Trial
– Reduce Inappropriate Therapy (MADIT-RIT) trial is a large-
scale randomized study designed to evaluate novel ICD pro-
gramming to reduce inappropriate therapy in patients with
primary prevention ICD or CRT-D. MADIT-RIT compared
conventional ICD programming with either high-rate therapy
or long delay before therapy delivery and showed that both
high-rate cutoff programming anddelayed therapy is associated
with a significant reduction in inappropriate ICD therapy.6,7
In this secondary analysis of MADIT-RIT, we aimed to
characterize the rates of different types of appropriate thera-
pies (antitachycardia pacing [ATP], shock, or both) for adju-
dicated ventricular arrhythmias (VAs) at or above 200 beats/
min by programming arm, rates at which the only difference
between the therapy groups is the time delay between VT
detection and therapy. We hypothesized that progressively
longer delays will result in a reduction in the number of
appropriate ICD therapies, whether ATP or shock, because
of the self-terminating nature of many fast VAs, rendering
early interventions premature and potentially unnecessary.
Methods
Study population
MADIT-RIT was a multicenter, randomized, prospective,
controlled clinical trial evaluating patients with approved indi-
cations for primary prevention ICD or CRT.8,9 The trial design
and results had been published previously.6,7 MADIT-RIT
was approved by the institutional review boards at the partici-
pating centers in accordance with the guidelines of the Decla-
ration of Helsinki. Briefly, patients were randomized to
standard ICD programming  170 beats/min (“arm A”), a
high-rate therapy cutoff  200 beats/min programming strat-
egy (“arm B”), or a prolonged detection duration (60 seconds
170 beats/min and 12 seconds 200 beats/min) strategy
(“arm C”) after a successful implantation of a dual-chamber
ICD or CRT-D device (Table 1). The primary end point of
the study was time to first inappropriate ICD therapy (either
ATP and/or shock). MADIT-RIT enrolled 1500 patients, 21
years or older, with ischemic or nonischemic systolic heart
failure. All patients met the guideline criteria for implantation
of primary prevention of ICD or CRT-D.8,9
MADIT-RIT was not prospectively designed to assess the
role of high-rate cutoff programming or therapy delay pro-
gramming in the frequency of appropriate ICD therapies
only; however, because of an extensive adjudication process
of all device interventions, we were able to retrospectively
analyze the behavior of all therapy modalities in VAs above
200 beats/min that received a therapeutic intervention.
Definitions and study end points
During the total study duration, first appropriate ICD therapy
event information was collected from device interrogations
and adjudicated by an independent panel according to pre-
specified criteria.7 Appropriate therapy was defined as any
therapy (ATP, shock, or both) delivered for any VAs. Only
episodes with available intracardiac electrograms were
included for appropriate adjudication. Given the memory
limitations of all ICDs, the arrhythmic events are stored chro-
nologically in such a way that the electrograms of prior
events may sometimes be erased from the device memory
to allow the display of the most recent events.
In this analysis, we evaluated the rates of first appropriate
therapy 200 beats/min treated with an ATP only, ATP and
shock, and shock only, stratified by ICD programming arm.
Because we eliminated all VAs events , 200 beats/min,
the only programming difference across the 3 ICD program-
ming arms was therapy delay (Table 1).
Statistical analysis
First appropriate ICD therapy events  200 beats/min treated
with ATP only, ATP and shock, and shock only are reported
as frequencies and percentages. The rates of first appropriate
ATP only and ATP and shock for VAs events  200 beats/
min were displayed by programming arm A (conventional) vs
arm B (high-rate cutoff) vs arm C (delayed therapy program-
ming).
Comparisons of first appropriate ATP only and ATP and
shock for VAs events  200 beats/min were performed be-
tween conventional arm A vs high-rate arm B and between
conventional arm A vs delayed therapy arm C by using the
c2 test for dichotomous variables. Dichotomous variables,
as two separate tests, since the original study design aimed
to compare these 2 ICD programming arms separately.
All statistical tests were 2-sided, and a P value of ,.05
was considered statistically significant. Analyses were per-
formed with SAS version 9.4 (SAS institute, Cary, NC).
Results
MADIT-RIT was a large-scale and well-balanced random-
ized clinical trial with no significant differences between
Table 1 Programming arms in MADIT-RIT for ventricular arrhythmias . 200 beats/min
Arm A (conventional) Arm B (high-rate cutoff) Arm C (therapy delay)
VF zone VF zone VF zone
200 beats/min, 1 s delay 200 beats/min, 2.5 s delay 200 beats/min, 12 s delay







ATP5 antitachycardia pacing; MADIT-RIT5 Multicenter Automatic Defibrillator Implantation Trial – Reduce Inappropriate Therapy; VF5 ventricular fibril-
lation.
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patient clinical characteristics across the different ICD pro-
gramming arms.6 In this analysis, we evaluated only VAs
events 200 beats/min for which the only programming dif-
ference across the 3 ICD programming arms was therapy
delay (Table 1).
Rates of ATP only, ATP and shock, and shock only
appropriate therapy events ‡ 200 beats/min
In MADIT-RIT arm A with conventional ICD programming,
59 patients (11.5%) had VAs  200 beats/min; 54 of them
(10.5%) were initially treated with ATP and 5 of them
(1%) with shock (VAs  250 beats/min at onset). The final
therapy, defined as the therapy modality preceding the return
to normal rhythm, was ATP in 41 patients (8%) and shock in
18 patients (3.5%). In arm B, 33 patients (6.6%) had VAs 
200 beats/min; 21 (4.2%) were initially treated with ATP and
12 (2.4%) with shock (VAs  250 beats/min at onset). The
final therapy was ATP in 14 patients (2.8%) and shock in
19 patients (3.8%). In arm C, 23 patients (4.7%) had VAs
 200 beats/min; 12 (2.5%) were initially treated with ATP
and 11 (2.3%) with shock (VAs  250 beats/min at onset).
The final therapy was ATP in 7 patients (1.4%) and shock
in 16 patients (3.3%). The final shock event rate was similar,
3.5%, 3.8%, and 3.3%, in arms A, B, and C, while ATP ther-
apy was significantly reduced between therapy arms,
revealing the influence of incrementally delayed therapy on
the incidence of ATP delivery (Table 2 and Figure 1).
The proportion of patients who received an appropriate
ICD therapy for VAs  200 beats/min in MADIT-RIT was
reduced by up to 62% when comparing the conventional
ICD programming arm (arm A) with the delayed therapy
ICD programming arm (arm C). When analyzed by the 2
types of ICD therapy, we find that this decrease was driven
almost entirely by a 78% reduction in the delivery of ATP.
Because MADIT-RIT was a large and well-balanced ran-
domized study, this outcome is likely the result of longer
therapy delays across study arms, allowing even longer “non-
sustained” VAs to self-terminate before therapy delivery as
illustrated in Figure 2.
Moreover, it is interesting to note that the apparent ATP
efficacy across ICD programming arms in MADIT-RIT ap-
pears to decrease (Figure 2). In arm A, the ATP success
rate is 75.9% (41 of 54 events); in arm B, it is 66.7% (14
of 21 events); and in arm C, it is 58.3% (7 of 12 events). Since
ATP was applied in some VAs that were destined to
self-terminate as mentioned above, the perceived efficacy
of ATP in patients with primary prevention ICDmay be over-
stated as well when applied prematurely.
Discussion
In this retrospective analysis of the MADIT-RIT cohort with
appropriate therapies at or above 200 beats/min, we clearly
demonstrated that increasing therapy delays resulted in
marked reductions in the utilization of ATP therapies as the
time to therapy was increased from 3.4 seconds (arm A) to
4.9 seconds (arm B) to 14.4 seconds (arm C). Furthermore,
the 2 types of ICD therapies (ATP or shock) revealed that
the incidence of appropriate shocks delivered for VAs 
200 beats/min was similar across all 3 arms with no signifi-
cant differences. The incidence of appropriate ATP in the
conventional ICD programming arm was 18% compared
with 5% in those with high-rate therapy programming and
2% in those with delayed therapy programming. These find-
ings altogether suggest a limited value of ATP for treating
fast VAs  200 beats/min with longer detection delays in a
population with primary prevention ICD as opposed to
high ATP efficacy in populations with secondary preven-
tion.4
The only plausible explanation for the above observations
is that as therapy delay is increased, many of the VAs self-
terminate. The importance of this observation is 2-fold: (1)
The value of ATP effectiveness in a population with primary
prevention could be overestimated in light that with long
therapy delays, many VAs are in fact self-terminating
without an ATP intervention. (2) Relatively long therapy de-
lays are well tolerated without an increase in cardiovascular
morbidity while enormously reducing the frequency of un-
necessary interventions, mainly ATP.
Interestingly, an analysis of mortality in MADIT-RIT10
revealed a statistically significant association between inap-
propriate ATP and all-cause mortality while no association
was found between appropriate ATP and all-cause mortality.
However, an association does not necessarily imply causal-
ity, and further investigation into ATP and its value in a pop-
ulation with primary prevention ICD is warranted.
Table 2 First appropriate ICD therapy delivered by MADIT-RIT ICD programming arm for ventricular arrhythmias  200 beats/min
Randomized arm Conventional therapy (n 5 514) High-rate therapy (n 5 500) Delayed therapy (n 5 486) P
Delay before ATP delivery after
detection
1 s 2.5 s 12 s
First episode—shock (ATP 1 shock,
shock alone)
18 (3.5%) 19 (3.8%) 16 (3.3%) .910
Shock for rate  250 beats/min 5 (1.0%) 12 (2.4%) 11 (2.3%) .178
Shock for failed appropriate ATP 13 (2.5%) 7 (1.4%) 5 (1.0%) 5.153
First episode—ATP alone 54 (10.5%) 21 (4.2%) 12 (2.5%) ,.0001
Total first episode 59 (11.5%) 33 (6.6%) 23 (4.7%) .0002
ATP 5 antitachycardia pacing; ICD 5 implantable cardioverter-defibrillator; MADIT-RIT 5 Multicenter Automatic Defibrillator Implantation Trial – Reduce
Inappropriate Therapy.
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The Pacing Fast Ventricular Tachycardia Reduces Shock
Therapies (PainFREE Rx II) study11 is the only multicenter
prospective randomized study that has previously evaluated
the efficacy of ATP for rapid VAs. Patients were randomized
to receive ATP or shocks only, with both arms programmed
to detection of 18 of 24 fast intervals at a rate cutoff of 188
beats/min. This study enrolled patients from January 2001
to March 2002 and included a mix of patients with mainly
secondary indications but ceased enrollment before the era
of primary prevention ICD indications. More than one-third
of episodes in the shock arm self-terminated during a median
capacitor charge time of 3.3 seconds, leading to the possibil-
ity that a longer detection time could have further reduced the
rate of ATP or shocks for VTs. Other studies that examined
the role of therapy delays, such as the Primary Prevention Pa-
rameters Evaluation study11 and the Avoid Delivering Ther-
apies for Nonsustained Arrhythmias in ICD Patients III
(ADVANCE-III) study,12 had considerably shorter therapy
Figure 1 The rate of first appropriate implantable cardioverter-defibrillator therapies (antitachycardia pacing [ATP] only, ATP and shock, and shock only) for
ventricular arrhythmias  200 beats/min in Multicenter Automatic Defibrillator Implantation Trial – Reduce Inappropriate Therapy by programming arms.
Figure 2 The rate of successful and failed antitachycardia pacing (ATP) across Multicenter Automatic Defibrillator Implantation Trial – Reduce Inappropriate
Therapy programming arms for ventricular arrhythmias  200 beats/min. NSVT 5 non-sustained ventricular tachycardia; Pct 5 percent.
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delays (an effective delay of w9 seconds) and included pa-
tients with both primary and secondary prevention indica-
tions. In a subanalysis of ADVANCE-III13 that specifically
tried to look at the value of ATP over a long detection inter-
val, the authors find an efficacy of only 52% in the long detec-
tion arm, similar to our finding when compared to the
standard detection interval arm. However, the authors
ascribed an additive value of ATP over long detections on
the basis of a hypothetical scenario that all tachycardias
that terminated during charging did so because of ATP at
the time of charging without considering the possibility of
self-termination. Moreover, the authors acknowledge that
ATP was less effective in patients with primary prevention
as opposed to patients with secondary prevention. As is the
case with our study, there was not statistically significant dif-
ference in the number of shocks delivered for VAs between
both arms of ADVANCE III.
The studies previously mentioned evaluated ATP inter-
ventions with the implicit assumption that termination of
those events was the result of the intervention. However,
application of longer delays in this study rendered up to
78% of ATP episodes unnecessary. This appropriately high-
lights that the risk/profile benefit of ATP in primary preven-
tion ICD recipients should be reexamined in a prospective
randomized trial given that the presumption of efficacy in a
pure primary prevention cohort remains unproven.
It is also worth mentioning that the number of patients
needing shock therapy was not statistically different across
ICD programming arms despite a massive reduction in
ATP events, suggesting that ATP-induced accelerations lead-
ing to sustained rapid VAs requiring shocks are uncommon, a
finding also reported in the ADVANCE III subanalysis.
Limitations
This analysis from MADIT-RIT is retrospective, and the
usual caveats about hypothesis-generating data analysis
apply. Moreover, given the small number of patients in
MADIT-RIT with delayed therapy who had ATP events, a
substantially larger prospective randomized controlled trial
will be necessary to confirm this hypothesis.
Conclusion
We conclude from the data of this secondary analysis of
MADIT-RIT that the value of ATP in patients with primary
prevention ICD may have been overestimated. ATP success
as previously reported in other studies potentially includes a
large proportion of patients who receive unnecessary ATP for
nonsustained VT destined to terminate spontaneously any-
way.
The ultimate value of ATP in a pure primary prevention
population remains speculative.
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